NCT03070886 2026-01-14
Antiandrogen Therapy and Radiation Therapy With or Without Docetaxel in Treating Patients With Prostate Cancer That Has Been Removed by Surgery
NRG Oncology
Phase 2/3 Completed
Clinical Trials
48 trialsNCT00117286 2025-12-18
Extension Study Investigating the Long-Term Safety of Degarelix One-Month Depots in Patients With Prostate Cancer
Ferring Pharmaceuticals
Phase 2/3 Completed
NCT05137561 2025-08-07
PROBIOP
Post Graduate Institute of Medical Education and Research, Chandigarh
Phase 2/3 Completed
NCT03822845 2025-04-17
Evaluating the Clinical Accuracy of Gallium-68 PSMA PET/CT Imaging in Patients With Biochemical Recurrence of Prostate Cancer
University of Iowa
Phase 2/3 Completed
NCT06601205 2024-09-19
2F
Ente Ospedaliero Ospedali Galliera
Phase 2/3 Completed
NCT03389451 2024-07-12
68Ga PSMA PET for Patients With Biochemical Recurrence of Prostate Cancer
University of Iowa
Phase 2/3 Completed
NCT03388346 2024-02-15
68Ga PSMA in Preprostatectomy Patients
University of Iowa
Phase 2/3 Completed
NCT00584532 2023-11-24
GCP
University of California, Davis
Phase 2/3 Completed
NCT02624518 2023-04-10
68Ga-RM2 PET/MRI in Biochemically Recurrent Prostate Cancer
Stanford University
Phase 2/3 Completed
NCT03103152 2023-03-29
PROVENT
Queen Mary University of London
Phase 2/3 Completed
NCT04627896 2023-02-02
Targeted Microwave Focal Therapy
A.O.U. Città della Salute e della Scienza
Phase 2/3 Completed
NCT01869413 2022-10-04
TACT
Ottawa Hospital Research Institute
Phase 2/3 Completed
NCT03410693 2022-09-28
FORT-1
Bayer
Phase 2/3 Completed
NCT02678351 2022-03-04
68Ga-PSMA-11 PET/MRI in Finding Tumors in Patients With Intermediate or High-Risk Prostate Cancer Undergoing Surgery
Stanford University
Phase 2/3 Completed
NCT02673151 2022-01-13
68Ga-PSMA PET/CT in Detecting Prostate Cancer Recurrence in Patients With Elevated PSA After Initial Treatment
Stanford University
Phase 2/3 Completed
NCT02981368 2021-08-09
OSPREY
Progenics Pharmaceuticals, Inc.
Phase 2/3 Completed
NCT01006395 2019-07-05
Prevention of Micro-architectural Bone Decay in Males With Non-metastatic Prostate Cancer Receiving Androgen Deprivation Therapy (ADT)
Austin Health
Phase 2/3 Completed
NCT02355886 2019-06-04
Gabapentin in Reducing the Need for Pain Medication in Patients With Bladder Cancer Undergoing Radical Cystectomy
University of Washington
Phase 2/3 Completed
NCT01668459 2018-12-04
CabB1
University Hospital Birmingham NHS Foundation Trust
Phase 2/3 Completed
NCT01206270 2018-09-25
ALCeP
University of Roma La Sapienza
Phase 2/3 Completed
NCT01105338 2018-01-23
ProDiet
University of Bristol
Phase 2/3 Completed
NCT02883153 2017-06-19
Zirconium-89-girentuximab PET/CT Imaging in Renal Cell Carcinoma
Radboud University Medical Center
Phase 2/3 Completed
NCT02935972 2017-01-23
Combined Intravenous Diazepam, Local Periprostatic Nerve Block for Prostate Biopsy
Assiut University
Phase 2/3 Completed
NCT02829775 2017-01-09
A Study of Continued Treatment Among Participants Who Have Responded to Peginterferon Alfa-2a (Pegasys®) or Recombinant Interferon Alfa-2a (Roferon-A®) in Prior Clinical Studies
Hoffmann-La Roche
Phase 2/3 Completed
NCT00553878 2016-10-14
AVIAS
Canadian Urology Research Consortium
Phase 2/3 Completed
NCT00389155 2015-12-07
First-Line Treatment of Advanced Bladder Cancer Randomized vs. Gemcitabine ± Vinflunine in Patients Ineligible to Receive Cisplatin-Based Therapy
Bristol-Myers Squibb
Phase 2/3 Completed
NCT00420888 2015-07-22
ABR-217620/Naptumomab Estafenatox With Interferon-alpha (IFN-alpha) Compared to IFN-alpha Alone in Patients With Advanced Renal Cell Carcinoma
Active Biotech AB
Phase 2/3 Completed
NCT01316874 2015-06-12
Bladder Cancer
Endo Pharmaceuticals
Phase 2/3 Completed
NCT02030717 2015-06-04
ASA
Umeå University
Phase 2/3 Completed
NCT01415375 2015-04-17
Prostate Cancer Education in African American Men
Temple University
Phase 2/3 Completed
NCT00215683 2015-04-01
An Extension Study Evaluating the Long-Term Safety and Tolerability of Degarelix One-Month Depots in Prostate Cancer
Ferring Pharmaceuticals
Phase 2/3 Completed
NCT01715064 2014-02-10
Acute Effects of Exercise on the Cortical Silent Period in Prostate Cancer Patients
University of Guelph-Humber
Phase 2/3 Completed
NCT00765479 2013-09-20
Soy Protein in Preventing Recurrent Cancer in Patients Who Have Undergone Surgery for Stage II Prostate Cancer
National Cancer Institute (NCI)
Phase 2/3 Completed
NCT01920269 2013-08-09
EMDA/MMC
University of Rome Tor Vergata
Phase 2/3 Completed
NCT01901042 2013-07-17
Efficacy of Symbiotic in the Reduction of Acute Radiation Proctitis Symptoms
Federal University of Mato Grosso
Phase 2/3 Completed
NCT00014274 2013-06-12
Combination Chemotherapy in Treating Patients With Transitional Cell Cancer of the Urothelium
European Organisation for Research and Treatment of Cancer - EORTC
Phase 2/3 Completed
NCT01825642 2013-04-05
Prospective Randomized Trial of Seminal Vesicle-Sparing Prostatectomy and Nerve-Sparing Radical Prostatectomy in Men With Clinically Localized Prostate Cancer
University of Michigan
Phase 2/3 Completed
NCT00006124 2013-02-13
Celecoxib in Treating Patients With Bladder Cancer
National Cancer Institute (NCI)
Phase 2/3 Completed
NCT01272648 2013-01-29
RePCa
Odense University Hospital
Phase 2/3 Completed
NCT00004071 2012-09-11
Mitoxantrone and Prednisone With or Without Leflunomide in Treating Patients With Stage IV Prostate Cancer
Pfizer
Phase 2/3 Completed
NCT00330707 2011-03-04
Combined Use of BCG and Interferon Alpha in Bladder Cancer
National University Hospital, Singapore
Phase 2/3 Completed
NCT00268892 2010-12-24
Extension Study Investigating the Long-Term Safety of Degarelix Three-Month Depots in Patients With Prostate Cancer
Ferring Pharmaceuticals
Phase 2/3 Completed
NCT00136487 2009-12-09
Celecoxib (Celebrex) Versus Placebo in Men With Recurrent Prostate Cancer
Dana-Farber Cancer Institute
Phase 2/3 Completed
NCT00127478 2007-11-29
A Long Term Safety Study With Atrasentan
Abbott
Phase 2/3 Completed
NCT00428428 2007-11-16
Pharmacological Modulation of the Intrarenal Pressure During Endourological Procedures in the Upper Urinary Tract
Fredericia Hosptial
Phase 2/3 Completed
NCT00421694 2007-10-08
Positive Surgical Margins Rate and EGFR Family Members Expression in Prostate Cancer Treated With Bicalutamide
University of L'Aquila
Phase 2/3 Completed
NCT00035334 2006-02-14
Study of the Safety and Efficacy of NC-503 in Secondary (AA) Amyloidosis
Bellus Health Inc. - a GSK company
Phase 2/3 Completed
NCT00164437 2005-09-14
CD-ROM Intervention for Prostate Cancer Screening
Centers for Disease Control and Prevention
Phase 2/3 Completed